Tikosyn Related Published Studies
Well-designed clinical trials related to Tikosyn (Dofetilide)
Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. [2007.09.01]
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. [2006.04]
Phase IV trial evaluating the effectiveness and safety of dofetilide. [2004.07]
The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. [2003.05]
Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. [2003.02]
A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. [2002.06]
Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. [2002.03]
Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval. [2002.01]
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. [2001.12]
Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. [2001.11]
A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. [2001.08]
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. [2001.07.17]
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. [2001.07]
Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. [2001.06.01]
Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. [2001.03.15]
Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. [2001.03.13]
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. [2000.12.16]
Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. [2000.11.07]
Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. [2000.11]
[Dofetilide to patients with heart failure and left ventricular dysfunction] [2000.10.30]
Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter. [2000.09.15]
The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. [2000.09]
Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. [2000.08]
Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial. [2000.06]
Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. [2000.01]
Effect of dofetilide on survival in patients with supraventricular arrhythmias. [1999.11]
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. [1999.09.16]
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. [1999.06]
Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. [1997.02]
Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. [1997.01.31]
Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. [1996.10.01]
Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. [1995.11]
A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. [1995.09]
Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. [1995.05]
Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs. [1994.11]
Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. [1993.03]
Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. [1992.12.01]
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. [1992.02.15]
Well-designed clinical trials possibly related to Tikosyn (Dofetilide)
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. [2007.02]
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. [2007.01.16]
Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. [2005]
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. [2004.03.30]
Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. [2003.12.16]
Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. [2001.09]
Effect of dofetillide on the pharmacokinetics of digoxin. [2001.01.15]
Pharmacological management of atrial fibrillation: an update. [2000.01]
Class III antiarrhythmic drugs. [1994.01]
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. [1991.10]
Other research related to Tikosyn (Dofetilide)
Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. [2010.09]
CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C epsilon in the myocardium. [2010.01]
Sex and age related differences in drug induced QT prolongation by dofetilide under reduced repolarization reserve in simulated ventricular cells. [2010]
Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation. [2009.11]
Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. [2009.10]
Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. [2009.07]
Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. [2009.07]
The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts. [2009.03]
The effect of dofetilide on ventricular defibrillation thresholds. [2009.01]
An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia. [2008.12]
Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. [2008.11]
Ultrafast sodium channel block by dietary fish oil prevents dofetilide-induced ventricular arrhythmias in rabbit hearts. [2008.10]
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. [2008.10]
The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. [2008.08]
Usefulness of dofetilide for the prevention of atrial tachyarrhythmias (atrial fibrillation or flutter) after coronary artery bypass grafting. [2008.06.01]
Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide. [2008.02]
Acute conversion of persistent atrial fibrillation during dofetilide initiation. [2007.12]
Dofetilide-induced long QT and torsades de pointes. [2007.07]
Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. [2007.04]
Management of dofetilide overdose in a patient with known cocaine abuse. [2007.03]
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. [2007.03]
Dofetilide: a new class III antiarrhythmic agent. [2007.01]
Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. [2006.02.27]
Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale. [2005.09]
Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes. [2005.08]
Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. [2005.08]
Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. [2004.11]
Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. [2004.06.16]
Ventricular arrhythmias triggered by alerting stimuli in conscious rabbits pre-treated with dofetilide. [2004.03]
Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. [2003.12]
Evaluation of the dofetilide risk-management program. [2003.11]
Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. [2003.09]
Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. [2003.09]
Dofetilide: a new drug to control cardiac arrhythmia. [2003.06]
Practitioner acceptance of the dofetilide risk-management program. [2002.08]
Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats. [2002.05]
Evaluation of Pulsincap to provide regional delivery of dofetilide to the human GI tract. [2002.04.02]
Practical approach to the use and monitoring of dofetilide therapy. [2001.11.01]
Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. [2001.11]
Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter. [2001.09]
Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. [2001.05]
Dofetilide (Tikosyn): a new drug to control atrial fibrillation. [2001.04]
The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. [2001.04]
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs. [2001.02]
Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. [2001.01.19]
Dofetilide: a new class III antiarrhythmic agent. [2001.01]
Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation. [2000.11]
Dofetilide: a new pure class III antiarrhythmic agent. [2000.11]
Dofetilide, a new class III antiarrhythmic agent. [2000.07]
Dofetilide: a class III-specific antiarrhythmic agent. [2000.01]
Dofetilide: a review of its use in atrial fibrillation and atrial flutter. [1999.12]
Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. [1999.02]
Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide. [1998.09]
|